Pharmaceutical formulation development and manufacturing services provider Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq:CBRX) has been selected as the formulation development partner for a major pan-European collaborative project.
The UK-based company has been chosen by clinical stage biopharmaceutical company Telormedix SA (Telormedix) to develop both topical and solid dosage formulations for the use in the treatment of psoriasis.
The project, operating under the acronym PAT (Psoriasis Anti-inflammatory Treatment), will involve other consortium partners Biopta, Midatech Biogune and the University Hospital Zurich. Telormedix raised funding from the European Eurostars Programme to coordinate this international research project for one of its promising drug candidates, TMX-302, which will use Midatech’s glycan-coated gold nanoparticles formulated using Molecular Profiles’ expertise.
Dr. Johanna Holldack, CEO at Telormedix, said: “We are absolutely delighted to have secured this funding with such a world class consortium to bring TMX-302 to pre-clinical proof of concept. The team at Molecular Profiles will play a key role in developing new oral and topical formulations of TMX-302, both of which are viewed as practicable administration options for the treatment of psoriasis.”The deal comes just weeks after Molecular Profiles announced the official opening of its new facility following a successful inspection from the Medical and Healthcare products Regulatory Agency (MHRA), and on the heels of its acquisition by Columbia Laboratories, a Boston-based company with a rich heritage in drug development. Molecular Profiles’ chief executive officer Nikin Patel said: “We are pleased to have been chosen as the formulation development partner for this high-profile, multi-partner project. Our team is ready to apply our technologies to deliver a robust topical and oral formulation.” “We anticipate that this is just the start of a longer-term clinical development and manufacturing initiative to support a future trial. Beyond the formulation work, our new facility gives Telormedix the reassurance we can also support their finished dosage form production requirements.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV